{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T13:49:11Z","timestamp":1658929751570},"reference-count":14,"publisher":"Medical Association of Nippon Medical School","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1272\/jnms.81.333","type":"journal-article","created":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T00:29:42Z","timestamp":1415838582000},"page":"333-336","source":"Crossref","is-referenced-by-count":3,"title":["Grade 4 Epistaxis in a Woman with Metastatic Breast Cancer Treated with Bevacizumab: A Case Report"],"prefix":"10.1272","volume":"81","author":[{"given":"Keiko","family":"Yanagihara","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Kurita","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Saegusa","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Davies C, Godin J, Gray R, et al.: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Slamon D, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.","DOI":"10.1056\/NEJM200103153441101"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gray R, Bhattacharya S, Bowden C, et al.: Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-4972.","DOI":"10.1200\/JCO.2008.21.6630"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.","DOI":"10.1056\/NEJMoa072113"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Miles DW, Chan A, Dirix LY, et al.: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.","DOI":"10.1200\/JCO.2008.21.6457"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Robert NJ, Dietas V, Glaspy J, et al.: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.","DOI":"10.1200\/JCO.2010.28.0982"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D: Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-1857.","DOI":"10.2174\/092986706777585059"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Matsune S: Allergic rhinitis and vascular endothelial growth factor. J Nippon Med Sch 2012; 79: 170-175.","DOI":"10.1272\/jnms.79.170"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999; 56: 794-814.","DOI":"10.1046\/j.1523-1755.1999.00610.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.","DOI":"10.1097\/00000421-198212000-00014"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998; 339: 974-984.","DOI":"10.1056\/NEJM199810013391407"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Aogi K, Masuda N, Ohno S, et al.: First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 2011; 129: 829-838.","DOI":"10.1007\/s10549-011-1685-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cella D, Wang M, Wagner L, Miller K: Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat 2011; 130: 855-861.","DOI":"10.1007\/s10549-011-1725-6"},{"key":"14","unstructured":"14. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/81\/5\/81_333\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T07:45:18Z","timestamp":1617003918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/81\/5\/81_333\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.81.333","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}